Latest News and Press Releases

Vor Bio Announces $175 Million Private Placement

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Vasculitis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's...

Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Cutaneous Lupus Erythematosus Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035"...

Autolus announces its operational and financial results for the first quarter ended March 31, 2025.

Novel, oral candidate with first-in-class potential progresses to regulatory non-clinical studies to support a Clinical Trial Authorisation First indication will be psoriatic arthritis, a...

Autolus presented updates on its development pipeline and plans for expansion in autoimmune diseases at an R&D investor event.

Autolus announces recent updates and financial results for the full year ended December 31, 2024.

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease...

Alumis to Present at Leerink's 2025 Global Healthcare Conference